Publications by authors named "E Saada"
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination and is challenging to replace with existing approaches.
View Article and Find Full Text PDFArticle Synopsis
- Viral populations in natural infections can vary widely genetically, affecting their ability to evade immune responses, yet most potency tests use a uniform viral strain, which may not reflect real-world scenarios.
- Researchers explored whether genetically diverse recombinant SARS-CoV-2 spike virus stocks could better represent circulating viruses by conducting passage experiments under selective pressures.
- Their findings showed that viral stocks passaged with selection pressure rapidly acquired mutations that helped them escape neutralization by monoclonal antibodies, suggesting that using genetically diverse stocks provides more accurate insights in antibody assessment assays.
Emerging and re-emerging viral pathogens present a unique challenge for anti-viral therapeutic development. Anti-viral approaches with high flexibility and rapid production times are essential for combating these high-pandemic risk viruses. CRISPR-Cas technologies have been extensively repurposed to treat a variety of diseases, with recent work expanding into potential applications against viral infections.
View Article and Find Full Text PDFArticle Synopsis
- This study compares survival outcomes between salvage total laryngectomy (TL) and primary TL in patients with advanced laryngeal or hypopharyngeal cancer, aiming to identify key predictive factors.
- The analysis included 234 patients and found that five-year overall survival was significantly lower for salvage TL (25%) compared to primary TL (53%), with several factors like tumor site and comorbidity impacting outcomes.
- The findings emphasize that salvage TL leads to worse survival rates, underscoring the importance of carefully selecting patients for larynx preservation and understanding predictive factors that influence treatment decisions.
Background: The aims of this study were to evaluate the clinical outcomes and their predictive factors in locally advanced hypopharyngeal cancer (HC) patients included in a docetaxel-cisplatin-fluorouracil induction chemotherapy (ICT)-based larynx preservation (LP) program.
Methods: Between 2005 and 2021, 82 patients with a locally advanced resectable HC who received ICT in an LP program were included in this retrospective study. The predictors of oncologic and swallowing outcomes were determined in univariate and multivariate analyses.